



(51) International Patent Classification:

C12N 9/26 (2006.01) A61P 1/00 (2006.01)
A61K 38/47 (2006.01) A61P 3/00 (2006.01)

(21) International Application Number:

PCT/US2025/012191

(22) International Filing Date:

17 January 2025 (17.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/621,997 17 January 2024 (17.01.2024) US

(71) Applicant: **ANAGRAM THERAPEUTICS, INC.**
[US/US]; 33 Strathmore Rd., Natick, Massachusetts 01760 (US).

(72) Inventors: **WELCH, Mark**; 25 Montalban Drive, Fremont, California 94536 (US). **GOVINDARAJAN, Sridhar**; 973 Campbell Ave., Los Altos, California 94024 (US). **MARGOLIN, Alexey**; 33 Strathmore Rd., Natick, Massachusetts 01760 (US). **GALLOTTO, Robert**; 34 Broad Acres Farm Road, Medway, Massachusetts 02053 (US).

BROWN, David; 97 Sewell Avenue, Brookline, Massachusetts 02446 (US).

(74) Agent: **MEYER, Mariah** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING CONGENITAL SUCRASE-ISOMALTASE DEFICIENCY




FIG. 1

(57) Abstract: Disclosed are recombinant mutant invertase enzymes. Also disclosed are pharmaceutical compositions comprising an invertase enzyme, e.g., a recombinant mutant invertase enzyme and an optional isomaltase enzyme. The enzymes and compositions can be used, among other things, to treat sucrase-isomaltase deficiency (e.g., congenital sucrase-isomaltase deficiency or acquired sucrase-isomaltase deficiency).

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*